334 related articles for article (PubMed ID: 28079862)
1. Extraneuronal pathology in a canine model of CLN2 neuronal ceroid lipofuscinosis after intracerebroventricular gene therapy that delays neurological disease progression.
Katz ML; Johnson GC; Leach SB; Williamson BG; Coates JR; Whiting REH; Vansteenkiste DP; Whitney MS
Gene Ther; 2017 Apr; 24(4):215-223. PubMed ID: 28079862
[TBL] [Abstract][Full Text] [Related]
2. Intracerebroventricular gene therapy that delays neurological disease progression is associated with selective preservation of retinal ganglion cells in a canine model of CLN2 disease.
Whiting REH; Jensen CA; Pearce JW; Gillespie LE; Bristow DE; Katz ML
Exp Eye Res; 2016 May; 146():276-282. PubMed ID: 27039708
[TBL] [Abstract][Full Text] [Related]
3. CLN2 Disease (Classic Late Infantile Neuronal Ceroid Lipofuscinosis).
Kohlschütter A; Schulz A
Pediatr Endocrinol Rev; 2016 Jun; 13 Suppl 1():682-8. PubMed ID: 27491216
[TBL] [Abstract][Full Text] [Related]
4. Enzyme replacement therapy attenuates disease progression in a canine model of late-infantile neuronal ceroid lipofuscinosis (CLN2 disease).
Katz ML; Coates JR; Sibigtroth CM; Taylor JD; Carpentier M; Young WM; Wininger FA; Kennedy D; Vuillemenot BR; O'Neill CA
J Neurosci Res; 2014 Nov; 92(11):1591-8. PubMed ID: 24938720
[TBL] [Abstract][Full Text] [Related]
5. Multifocal retinopathy in Dachshunds with CLN2 neuronal ceroid lipofuscinosis.
Whiting RE; Pearce JW; Castaner LJ; Jensen CA; Katz RJ; Gilliam DH; Katz ML
Exp Eye Res; 2015 May; 134():123-32. PubMed ID: 25697710
[TBL] [Abstract][Full Text] [Related]
6. Enzyme replacement therapy delays pupillary light reflex deficits in a canine model of late infantile neuronal ceroid lipofuscinosis.
Whiting RE; Narfström K; Yao G; Pearce JW; Coates JR; Castaner LJ; Jensen CA; Dougherty BN; Vuillemenot BR; Kennedy D; O'Neill CA; Katz ML
Exp Eye Res; 2014 Aug; 125():164-72. PubMed ID: 24954537
[TBL] [Abstract][Full Text] [Related]
7. AAV gene transfer delays disease onset in a TPP1-deficient canine model of the late infantile form of Batten disease.
Katz ML; Tecedor L; Chen Y; Williamson BG; Lysenko E; Wininger FA; Young WM; Johnson GC; Whiting RE; Coates JR; Davidson BL
Sci Transl Med; 2015 Nov; 7(313):313ra180. PubMed ID: 26560358
[TBL] [Abstract][Full Text] [Related]
8. Nonclinical evaluation of CNS-administered TPP1 enzyme replacement in canine CLN2 neuronal ceroid lipofuscinosis.
Vuillemenot BR; Kennedy D; Cooper JD; Wong AM; Sri S; Doeleman T; Katz ML; Coates JR; Johnson GC; Reed RP; Adams EL; Butt MT; Musson DG; Henshaw J; Keve S; Cahayag R; Tsuruda LS; O'Neill CA
Mol Genet Metab; 2015 Feb; 114(2):281-93. PubMed ID: 25257657
[TBL] [Abstract][Full Text] [Related]
9. Intravitreal implantation of TPP1-transduced stem cells delays retinal degeneration in canine CLN2 neuronal ceroid lipofuscinosis.
Tracy CJ; Whiting RE; Pearce JW; Williamson BG; Vansteenkiste DP; Gillespie LE; Castaner LJ; Bryan JN; Coates JR; Jensen CA; Katz ML
Exp Eye Res; 2016 Nov; 152():77-87. PubMed ID: 27637672
[TBL] [Abstract][Full Text] [Related]
10. Intrathecal tripeptidyl-peptidase 1 reduces lysosomal storage in a canine model of late infantile neuronal ceroid lipofuscinosis.
Vuillemenot BR; Katz ML; Coates JR; Kennedy D; Tiger P; Kanazono S; Lobel P; Sohar I; Xu S; Cahayag R; Keve S; Koren E; Bunting S; Tsuruda LS; O'Neill CA
Mol Genet Metab; 2011 Nov; 104(3):325-37. PubMed ID: 21784683
[TBL] [Abstract][Full Text] [Related]
11. Diagnosis of neuronal ceroid lipofuscinosis type 2 (CLN2 disease): Expert recommendations for early detection and laboratory diagnosis.
Fietz M; AlSayed M; Burke D; Cohen-Pfeffer J; Cooper JD; Dvořáková L; Giugliani R; Izzo E; Jahnová H; Lukacs Z; Mole SE; Noher de Halac I; Pearce DA; Poupetova H; Schulz A; Specchio N; Xin W; Miller N
Mol Genet Metab; 2016 Sep; 119(1-2):160-7. PubMed ID: 27553878
[TBL] [Abstract][Full Text] [Related]
12. Mutation update: Review of TPP1 gene variants associated with neuronal ceroid lipofuscinosis CLN2 disease.
Gardner E; Bailey M; Schulz A; Aristorena M; Miller N; Mole SE
Hum Mutat; 2019 Nov; 40(11):1924-1938. PubMed ID: 31283065
[TBL] [Abstract][Full Text] [Related]
13. Intracranial delivery of CLN2 reduces brain pathology in a mouse model of classical late infantile neuronal ceroid lipofuscinosis.
Passini MA; Dodge JC; Bu J; Yang W; Zhao Q; Sondhi D; Hackett NR; Kaminsky SM; Mao Q; Shihabuddin LS; Cheng SH; Sleat DE; Stewart GR; Davidson BL; Lobel P; Crystal RG
J Neurosci; 2006 Feb; 26(5):1334-42. PubMed ID: 16452657
[TBL] [Abstract][Full Text] [Related]
14. Intravitreal enzyme replacement preserves retinal structure and function in canine CLN2 neuronal ceroid lipofuscinosis.
Whiting REH; Pearce JW; Vansteenkiste DP; Bibi K; Lim S; Robinson Kick G; Castaner LJ; Sinclair J; Chandra S; Nguyen A; O'Neill CA; Katz ML
Exp Eye Res; 2020 Aug; 197():108130. PubMed ID: 32622066
[TBL] [Abstract][Full Text] [Related]
15. Cynomolgus macaque model of neuronal ceroid lipofuscinosis type 2 disease.
Munesue Y; Ageyama N; Kimura N; Takahashi I; Nakayama S; Okabayashi S; Katakai Y; Koie H; Yagami KI; Ishii K; Tamaoka A; Yasutomi Y; Shimozawa N
Exp Neurol; 2023 May; 363():114381. PubMed ID: 36918063
[TBL] [Abstract][Full Text] [Related]
16. Large-volume intrathecal enzyme delivery increases survival of a mouse model of late infantile neuronal ceroid lipofuscinosis.
Xu S; Wang L; El-Banna M; Sohar I; Sleat DE; Lobel P
Mol Ther; 2011 Oct; 19(10):1842-8. PubMed ID: 21730969
[TBL] [Abstract][Full Text] [Related]
17. A novel CLN2/TPP1 mutation in a patient with late infantile neuronal ceroid lipofuscinosis.
Yu F; Liu XM; Chen YH; Zhang SQ; Wang K
Neurol Sci; 2015 Oct; 36(10):1917-9. PubMed ID: 26032578
[No Abstract] [Full Text] [Related]
18. Recombinant human tripeptidyl peptidase-1 infusion to the monkey CNS: safety, pharmacokinetics, and distribution.
Vuillemenot BR; Kennedy D; Reed RP; Boyd RB; Butt MT; Musson DG; Keve S; Cahayag R; Tsuruda LS; O'Neill CA
Toxicol Appl Pharmacol; 2014 May; 277(1):49-57. PubMed ID: 24642058
[TBL] [Abstract][Full Text] [Related]
19. Human iPSC models of neuronal ceroid lipofuscinosis capture distinct effects of TPP1 and CLN3 mutations on the endocytic pathway.
Lojewski X; Staropoli JF; Biswas-Legrand S; Simas AM; Haliw L; Selig MK; Coppel SH; Goss KA; Petcherski A; Chandrachud U; Sheridan SD; Lucente D; Sims KB; Gusella JF; Sondhi D; Crystal RG; Reinhardt P; Sterneckert J; Schöler H; Haggarty SJ; Storch A; Hermann A; Cotman SL
Hum Mol Genet; 2014 Apr; 23(8):2005-22. PubMed ID: 24271013
[TBL] [Abstract][Full Text] [Related]
20. Long-term expression and safety of administration of AAVrh.10hCLN2 to the brain of rats and nonhuman primates for the treatment of late infantile neuronal ceroid lipofuscinosis.
Sondhi D; Johnson L; Purpura K; Monette S; Souweidane MM; Kaplitt MG; Kosofsky B; Yohay K; Ballon D; Dyke J; Kaminksy SM; Hackett NR; Crystal RG
Hum Gene Ther Methods; 2012 Oct; 23(5):324-35. PubMed ID: 23131032
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
